Please assess the completion status of the following clinical trial:

Trial Title: Acute Pudendal Nerve Stimulation On Leak Point Pressure In Women Urodynamic Early Feasibility Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women between the ages of 18 and 85 years old, inclusive.~* Implanted with a neurostimulation device for at least 3 months prior to consent (Medtronic Interstim neurostimulator models 3023, 3058, 97810, or similar).~* Implanted with a tined lead that is placed and functionable at the pudendal nerve (Medtronic model 3889 or similar).~* Is capable of understanding clinical study procedures and giving informed consent.~* Willing and able to visit the clinic for the UDT evaluation (study procedure)~Exclusion Criteria:~* Medically unstable at time of study and unsafe to undergo urodynamic testing as determined by the investigator.~* History of bladder cancer.~* History of pelvic radiotherapy.~* Active gross hematuria.~* Active symptomatic urinary tract infection (UTI)~* Active symptomatic uncontrolled bladder instability as determined by the investigator.~* History or symptoms of cystocele, enterocele, or rectocele of grade 3 or 4. Per the medical record or as determined by the investigator.~* Presence of an artificial urinary sphincter.~* Women who are pregnant and/or have given birth in the previous 12 months~* Any medical condition that would interfere with the patient's ability to comply with the protocol and/or may affect the outcome of this study or safety of the subject as determined by the investigator~* BMI greater than 39.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Urodynamic testing with and without pudendal nerve stimulation (Type: OTHER): The neuromodulation settings of the implanted device will be adjusted to deliver acute simulation. Urodynamic testing (UDT) will be completed by filling the bladder and observing for urinary leakage. The assessment will be completed with the stimulation sets turned off and then turned on. At the end of the UDT the settings will be returned to the previously set therapeutic values. The neuromodulation settings constitute the dose and can include the voltage/current amplitude, frequency, pulse width, on time/off time duration and electrode polarity assignments. These parameters are limited by the available ranges of the approved neurostimulation device and will be adjusted during the study by the principal investigator to stay within the safe and comfortable levels for each individual study subject.

Based on this trial design, predict the completion outcome and termination type (if applicable).